Recombinant Human PSEN1 Protein，His

The study of PSEN1 (Presenilin-1), a key component of the γ-secretase complex, is pivotal in understanding Alzheimer's disease (AD), particularly familial forms of the disorder. PSEN1 mutations are among the most common genetic factors linked to early-onset AD, as they disrupt normal amyloid precursor protein (APP) processing, leading to the accumulation of neurotoxic amyloid-beta (Aβ) peptides in the brain. As a result, researchers are investigating PSEN1 recombinant proteins to elucidate the molecular mechanisms underlying its function and the impact of pathogenic mutations. By expressing and characterizing PSEN1 variants in vitro, scientists aim to explore how specific mutations alter the protein's conformation, enzymatic activity, and interaction with other components of the γ-secretase complex. Such studies are essential for designing targeted therapeutic strategies and potential interventions to mitigate the destructive pathways activated by aberrant Aβ accumulation. Additionally, the ability to produce recombinant PSEN1 proteins in sufficient quantities allows for further biochemical assays and drug screening efforts, promoting advancements in the development of effective treatments for Alzheimer's disease and related neurodegenerative disorders.